Pregnancy, childbirth and the puerperium. The codes included in this chapter are to be used for conditions related to or aggravated by the pregnancy, childbirth or by the puerperium (maternal causes or obstetric causes)
Conditions
Interventions
Dinoprostone 2mg vaginal gel (Glandin E2) inserted high into posterior fornix. dose repeated (if required and prescribed by doctor) after six hours of first dose..
Treatment - Drugs
Dinoprostone 2mg vaginal gel (Glandin E2) inserted high into posterior fornix. dose repeated (if required and prescribed by doctor) after six hours of first dose.
Sponsors
Nabiqasim Industries (Pvt) Ltd.
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Pregnant women; scheduled for labor induction with 2mg Dinoprostone vaginal gel; bishop score less than or equal to 4. Exclusion criteria: Bishop score greater then 4.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Increase of 3 in bishop score. Timepoint: six hours and 12 hours after dosing. Method of measurement: Bishop scoring method.;Attainment of bishop score of 6 or more. Timepoint: six and 12 hours after dosing. Method of measurement: Bishop scoring method.;Vaginal delivery occurring within 12 hours of dosing. Timepoint: occurring within 12 hours of dosing. Method of measurement: subject monitoring. | — |
Secondary
| Measure | Time frame |
|---|---|
| Maternal adverse events. Timepoint: from dosing to delivery. Method of measurement: Patient monitoring.;Neonatal adverse events. Timepoint: just after birth at 1 & 5 minutes. Method of measurement: APGAR score.;Fetal Adverse events. Timepoint: two hours after dosing, at six & 12 hours after dosing (till baby is not delivered). Method of measurement: by measuring CTG. | — |
Countries
Pakistan
Contacts
Public ContactSalman Rahim
Nabiqasim Industries (Pvt) Ltd.
Outcome results
None listed